| Title | Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavir. |
| Publication Type | Journal Article |
| Year of Publication | 2006 |
| Authors | McCance-Katz, Elinore F., David E. Moody, Patrick F. Smith, Gene D. Morse, Gerald Friedland, Patricia Pade, Jennifer Baker, Anika Alvanzo, Peter Jatlow, and Petrie M. Rainey |
| Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| Volume | 43 Suppl 4 |
| Pagination | S235-46 |
| Date Published | 2006 Dec 15 |
| ISSN | 1537-6591 |
| Keywords | Adult, Buprenorphine, Case-Control Studies, Cohort Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Drug Interactions, Female, HIV Protease Inhibitors, HIV Seronegativity, Humans, Lopinavir, Male, Narcotic Antagonists, Nelfinavir, Opioid-Related Disorders, Probability, Pyrimidinones, Reference Values, Risk Assessment, Ritonavir |
| Abstract | We examined drug interactions between buprenorphine, an opioid partial agonist available by prescription for treatment of opioid dependence, and the protease inhibitors (PIs) nelfinavir (NFV), ritonavir (RTV), and lopinavir/ritonavir (LPV/R). Opioid-dependent, buprenorphine/naloxone-maintained, human immunodeficiency virus (HIV)-negative volunteers (n=10 per PI) participated in 24-h pharmacokinetic studies, before and after administration of each PI. Symptoms of opiate withdrawal and excess were determined before and after PI administration. PI pharmacokinetics were determined and compared between opiate-dependent participants and healthy control participants (n=15 per PI). Administration of RTV, but not of NFV or LPV/R, resulted in a significant increase in the buprenorphine area under the concentration-time curve (AUC). Symptoms of opiate excess, however, were not observed. Buprenorphine had no significant effects on PI AUC. Adjustments of doses of either buprenorphine or NFV, LPV/R, or RTV are not likely to be necessary when these drugs are administered for the treatment of opioid dependence and HIV disease. |
| DOI | 10.3109/00952990.2011.568081 |
| Alternate Journal | Clin. Infect. Dis. |
